---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-032917"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:14:24.433664+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aquestive reports positive topline PK data for Anaphylm self-administration study

## Summary
- Self-administration PK study met primary endpoints; PK comparable whether administered by subjects or HCPs.
- Median Tmax of 15 minutes for Anaphylm self-admin & HCP-admin vs 50 minutes for Adrenalin IM injection in 36 healthy adults.
- Remaining supportive OAS challenge study underway, expected completion late Q3 or early Q4 2024.
- Company maintains NDA filing guidance late Q4 2024/early Q1 2025 and product launch by end 2025 or Q1 2026.

## SEC filing metadata
- accession: 0001628280-24-032917
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828024032917/0001628280-24-032917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828024032917/aqst-20240725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-032917
- JSON: https://secwatch.observer/filing/0001628280-24-032917.json
- Plain text: https://secwatch.observer/filing/0001628280-24-032917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.